Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAREON-Lung-1
CTR20261136Phase 3Active
- Sponsor
- 不适用/ 勃林格殷格翰(中国)投资有限公司
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of obrixtamig in small cell lung cancer (SCLC), sponsored by 不适用/ 勃林格殷格翰(中国)投资有限公司. Started Jun 2026; status: active.
02
Drugs
obrixtamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20261136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261136.